Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Interius BioTherapeutics announced today that it has entered into a definitive agreement to be acquired by Kite, a Gilead Company, for $350 million in cash.…
Philadelphia-based Interius is part of a group of young biotechs aiming to overcome the limitations of ex vivo cell therapy by manufacturing the therapeutic…
Gilead's Kite Pharma is acquiring Interius BioTherapeutics for $350 million in cash, a bet that in vivo CAR-T therapies can overcome the cost, complexity, and…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Gilead's Kite subsidiary agreed to acquire Interius BioTherapeutics for $350M, gaining in vivo CAR-T platform technology and INT2104, one of the first in vivo cell therapies in human trials. Integrates into Kite's Philadelphia research team.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / Interius BioTherapeutics, Inc. (this deal) | 2025 | $350M | — |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Nurix Therapeutics Inc. | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Immunomedics Inc. | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
← Browse all deals · How we score deals
More: 2025 deals · Gilead Sciences Inc. deals · Hematology deals